EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Refractory Post-Transplant Erythrocytosis in a Renal Transplant Recipient: A Case Report

Ahmed Mustafa, Abbas Gain, Umm E Salma Shabbar Banatwala, Nasim Salimiaghdam, Amir Kamran

Journal of Community Hospital Internal Medicine Perspectives · 17.03.2026 · 16 (2) · 76-79

DOI: 10.55729/2000-9666.1574 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Community Hospital Internal Medicine Perspectives, online erschienen am 17.03.2026. Verfasst von Ahmed Mustafa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Capital Health Internal Medicine Residency Program, Trenton, NJ, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Post-transplant erythrocytosis (PTE) is a well-recognized complication occurring in approximately 8–15% of renal transplant recipients. It is commonly managed with renin-angiotensin system (RAS) inhibitors, including angiotensin receptor blockers (ARBs). However, a subset of patients may be refractory to standard pharmacologic therapy. Case Presentation: We report the case of a 57-year-old male kidney transplant recipient who developed persistent erythrocytosis despite treatment with an ARB. The patient remained symptomatic with elevated hematocrit levels, prompting consideration of alternative management strategies. Management and Outcome: Given the inadequate response to RAS blockade, therapeutic phlebotomy was initiated. The patient tolerated the procedure well, and phlebotomy was effective in achieving long-term hematocrit control and symptom relief. No significant complications were observed during follow-up.

Conclusion

This case underscores the need for individualized management in patients with refractory PTE. It demonstrates the safe and effective use of therapeutic phlebotomy when pharmacologic interventions fail. The variability in treatment response suggests a need for flexible hematocrit targets and emphasizes monitoring of clinical symptoms in addition to laboratory values. Further research is needed to establish optimal treatment strategies and identify predictors of resistance to RAS blockade.

Schlagwörter

Stichwörter der Autor:innen

Post-transplant erythrocytosisRefractory erythrocytosisRenal transplant

Autor:innen und Institutionen

  • Department of Medicine, Capital Health Internal Medicine Residency Program, Trenton, NJ, United States.
  • Department of Medicine, Charleston Area Medical Center, Charleston, WV, United States.
  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Hematology & Oncology, Charleston Area Medical Center, Charleston, WV, United States.

Zitieren

APA

Mustafa, A., Gain, A., Salma Shabbar Banatwala, U. E., Salimiaghdam, N., & Kamran, A. (2026). Refractory Post-Transplant Erythrocytosis in a Renal Transplant Recipient: A Case Report. Journal of Community Hospital Internal Medicine Perspectives, 16(2), 76-79. https://doi.org/10.55729/2000-9666.1574

Vancouver

Mustafa A, Gain A, Salma Shabbar Banatwala UE, Salimiaghdam N, Kamran A. Refractory Post-Transplant Erythrocytosis in a Renal Transplant Recipient: A Case Report. Journal of Community Hospital Internal Medicine Perspectives. 2026;16(2):76-79. doi:10.55729/2000-9666.1574

BibTeX
@article{Mustafa2026,
  author = {Mustafa, Ahmed and Gain, Abbas and Salma Shabbar Banatwala, Umm E and Salimiaghdam, Nasim and Kamran, Amir},
  title = {Refractory Post-Transplant Erythrocytosis in a Renal Transplant Recipient: A Case Report},
  journal = {Journal of Community Hospital Internal Medicine Perspectives},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {76--79},
  doi = {10.55729/2000-9666.1574}
}
Kostenlos starten →